Post-approval studies (Phase 4)Ended earlyNCT03118713
What this trial is testing
Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria
Who this might be right for
Type 2 Diabetes Mellitus
Astellas Pharma Korea, Inc. 33